Ebola Outbreak in DR Congo: Over 300 Cases Confirmed Amid WHO Response

The Democratic Republic of the Congo (DRC) is confronting its latest Ebola outbreak with confirmed cases now exceeding 300, according to official reports, as health authorities race to contain the virus while treating patients and monitoring emerging risks beyond the region. The outbreak, caused by the Bundibugyo ebolavirus (BDBV), a less common but still deadly strain, has prompted a coordinated response from the World Health Organization (WHO) and Congolese health officials, who are balancing containment efforts with signs of progress in recovery rates.

As of June 2026, the WHO and DRC Ministry of Health have documented more than 300 confirmed Ebola cases, including at least five recoveries since the outbreak was declared in early 2026. The epicenter remains in eastern Congo, where a new treatment center has opened to accommodate patients and reduce transmission risks. However, the emergence of suspected cases outside Africa—though not yet confirmed—has raised concerns about potential cross-border spread, complicating global health surveillance.

Outbreak Details and Response

A joint statement from the DRC government and WHO confirmed the outbreak is caused by the Bundibugyo virus, a rare variant of Ebola that has historically accounted for only a fraction of recorded cases. Unlike the more widely studied Zaire ebolavirus, which caused the 2014–2016 West Africa outbreak, BDBV has a lower fatality rate but remains highly infectious. Health officials emphasize that early detection, isolation and experimental treatments—including monoclonal antibodies—are critical to controlling the spread.

The WHO’s latest updates highlight the opening of a dedicated Ebola treatment center in North Kivu province, a region already grappling with conflict and limited healthcare infrastructure. The facility aims to reduce mortality by providing intravenous fluids, supportive care, and, in some cases, experimental therapies. Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, visited the epicenter in late May, where he underscored the need for “urgent, sustained action” to prevent further transmission.

To date, five patients have recovered from the virus, a development that health officials describe as a sign of hope amid the crisis. However, the outbreak’s trajectory remains unpredictable. The DRC has faced repeated Ebola epidemics since 1976, with past outbreaks often exacerbated by armed conflict, displacement, and distrust in health systems. This time, the response includes enhanced community engagement and rapid deployment of vaccines for high-risk contacts.

Medical and Public Health Context

Ebola viruses are transmitted through direct contact with bodily fluids from infected individuals or contaminated surfaces. Symptoms include fever, muscle pain, vomiting, diarrhea, and, in severe cases, internal and external bleeding. The incubation period ranges from 2 to 21 days, making early detection challenging. While no licensed vaccine exists for BDBV, the WHO has approved the use of the Ervebo vaccine—developed for the Zaire strain—for ring vaccination of contacts in this outbreak, though its efficacy against BDBV is under study.

Experimental treatments, such as monoclonal antibody cocktails like mAb114 and REGN-EB3, have shown promise in clinical trials for other Ebola strains. However, their availability in conflict-affected regions remains limited. The WHO’s Strategic Advisory Group of Experts (SAGE) is reviewing data to determine whether these therapies should be prioritized for BDBV cases.

Public health experts warn that the outbreak’s location—near porous borders with Uganda, Rwanda, and South Sudan—heightens the risk of cross-border transmission. The DRC has activated regional alert systems, but the recent emergence of suspected cases outside Africa, as reported by Reuters, has not yet been confirmed by the WHO. If verified, such cases would mark the first time BDBV has been documented beyond the continent, necessitating global vigilance.

Challenges and Uncertainties

Despite progress in treatment and surveillance, significant challenges persist. Armed groups in eastern Congo have disrupted health operations in the past, and misinformation about Ebola can fuel resistance to vaccination campaigns. The WHO and partners are working to strengthen trust through local leaders and faith-based organizations.

Uncertainties remain about the outbreak’s duration and whether it will evolve into a larger epidemic. Historical data suggest BDBV outbreaks tend to be shorter than those caused by the Zaire strain, but the current context—combining a novel strain, conflict, and limited resources—makes predictions difficult. The WHO’s Emergency Committee will reconvene in the coming weeks to assess whether the outbreak constitutes a Public Health Emergency of International Concern (PHEIC), a designation that could trigger global funding and coordination.

For now, the focus remains on containment, treatment, and monitoring. The DRC’s health ministry and WHO are urging neighboring countries to enhance screening at border crossings and prepare their health systems for potential cases. Travelers to the region are advised to avoid contact with sick individuals and adhere to hygiene protocols, though routine precautions—such as handwashing—remain the most effective prevention measures for the general public.

As the situation develops, the WHO and partners will continue to provide updates through official channels. For the latest guidance, the public is directed to the World Health Organization’s Ebola response page and the DRC Ministry of Health’s communications.